RCC106807-4

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number
WO 01/00206 A1

(51) International Patent Classification[7]: A61K 31/40, 31/4025, C07D 207/12, 207/14, 401/12, 403/12

(21) International Application Number: PCT/US00/18079

(22) International Filing Date: 30 June 2000 (30.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/141,601	30 June 1999 (30.06.1999)	US
60/141,602	30 June 1999 (30.06.1999)	US
60/141,692	30 June 1999 (30.06.1999)	US

(71) Applicants *(for all designated States except US)*: **DAIICHI PHARMACEUTICAL CO., LTD.** [JP/JP]; Tokyo R & D Center, 16-13, Kita-Kasai 1-chome, Edogawa-ku, Tokyo 134-8630 (JP). **PHARMACOPEIA, INC.** [US/US]; 3000 Eastpark Blvd., Cranbury, NJ 08512 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BALDWIN, John, J.** [US/US]; 621 Gypsy Hill Circle, Gwynedd Valley, PA 19437 (US). **MCDONALD, Edward** [GB/US]; 1 Alvamar Court, Skillman, NJ 08558 (US). **MORIARTY, Kevin, Joseph** [US/US]; 3008 Greenridge Drive, Norristown, PA 19403 (US). **SARKO, Christopher, Ronald** [US/US]; 9 Fabian Place, Trenton, NJ 08638 (US). **MACHINAGA, Nobuo** [JP/JP]; 16-13, Kita-Kasai 1-chome, Edogawa-ku, Tokyo 134-8630 (JP). **NAKAYAMA, Atsushi** [JP/JP]; 16-13, Kita-Kasai 1-chome, Edogawa-ku, Tokyo 134-8630 (JP). **CHIBA, Jun** [JP/JP]; 16-13, Kita-Kasai 1-chome, Edogawa-ku, Tokyo 134-8630 (JP). **IIMURA, Shin** [JP/JP]; 16-13, Kita-Kasai 1-chome, Edogawa-ku, Tokyo 134-8630 (JP). **YONEDA, Yoshiyuki** [JP/JP]; 16-13, Kita-Kasai 1-chome, Edogawa-ku, Tokyo 134-8630 (JP).

(74) Agents: **CLEMENT, Candice, J.** et al.; Heslin & Rothenberg, P.C., 5 Columbia Circle, Albany, NY 12203 (US).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*
— *With amended claims.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VLA-4 INHIBITOR COMPOUNDS



(I)

(57) Abstract: Compounds that selectively inhibit the binding of ligands to α4β1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by formula (I). As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.

WO 01/00206 A1